CN101466678B - 作为蛋白激酶抑制剂的经取代3-氰基吡啶 - Google Patents

作为蛋白激酶抑制剂的经取代3-氰基吡啶 Download PDF

Info

Publication number
CN101466678B
CN101466678B CN2007800216875A CN200780021687A CN101466678B CN 101466678 B CN101466678 B CN 101466678B CN 2007800216875 A CN2007800216875 A CN 2007800216875A CN 200780021687 A CN200780021687 A CN 200780021687A CN 101466678 B CN101466678 B CN 101466678B
Authority
CN
China
Prior art keywords
indol
nicotinonitrile
methyl
amino
ylamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2007800216875A
Other languages
English (en)
Chinese (zh)
Other versions
CN101466678A (zh
Inventor
德里克·塞西尔·科尔
黛安娜·哈里斯·博斯谢利
亚农·丹尼尔·王
玛格达·阿瑟兰
黛安娜·玛丽·约瑟夫-麦卡锡
阿玛诺斯·沙斯特里·普拉沙德
艾伦·维斯纳
鲁塞尔·杜申
武必琪
劳伦斯·内森·汤米
川·S·牛
琼·陈
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth LLC filed Critical Wyeth LLC
Publication of CN101466678A publication Critical patent/CN101466678A/zh
Application granted granted Critical
Publication of CN101466678B publication Critical patent/CN101466678B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • C07D213/85—Nitriles in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN2007800216875A 2006-06-13 2007-06-13 作为蛋白激酶抑制剂的经取代3-氰基吡啶 Expired - Fee Related CN101466678B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81306006P 2006-06-13 2006-06-13
US60/813,060 2006-06-13
PCT/US2007/013954 WO2007146376A2 (en) 2006-06-13 2007-06-13 Substituted 3-cyanopyridines as protein kinase inhibitors

Publications (2)

Publication Number Publication Date
CN101466678A CN101466678A (zh) 2009-06-24
CN101466678B true CN101466678B (zh) 2012-12-26

Family

ID=38738795

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2007800216875A Expired - Fee Related CN101466678B (zh) 2006-06-13 2007-06-13 作为蛋白激酶抑制剂的经取代3-氰基吡啶

Country Status (18)

Country Link
EP (1) EP2029543B1 (enExample)
JP (1) JP2009539998A (enExample)
KR (1) KR20090018612A (enExample)
CN (1) CN101466678B (enExample)
AR (1) AR061368A1 (enExample)
AU (1) AU2007258237A1 (enExample)
BR (1) BRPI0712737A2 (enExample)
CA (1) CA2654515C (enExample)
CL (1) CL2007001737A1 (enExample)
ES (1) ES2558706T3 (enExample)
IL (1) IL194625A0 (enExample)
MX (1) MX2008015802A (enExample)
NO (1) NO20084739L (enExample)
PE (1) PE20080336A1 (enExample)
RU (1) RU2008139079A (enExample)
TW (1) TW200815407A (enExample)
WO (1) WO2007146376A2 (enExample)
ZA (1) ZA200810573B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2007001738A1 (es) * 2006-06-13 2008-01-18 Wyeth Corp Compuestos derivados de cianopiridinas; composicion farmaceutica; y uso para el tratamiento o inhibicion de un trastorno mediado por una proteina quinasa, tal como enfermedad autoinmune e inflamatoria.
WO2010026122A1 (en) 2008-09-02 2010-03-11 Novartis Ag Heterocyclic pim-kinase inhibitors
CN113735785B (zh) * 2020-05-28 2023-10-13 南京桦冠生物技术有限公司 3,6-二氯吡嗪-2-甲腈的制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1320121A (zh) * 1998-09-29 2001-10-31 美国氰胺公司 作为蛋白质酪氨酸激酶抑制剂的取代的3－氰基喹啉
CN1659145A (zh) * 2001-11-27 2005-08-24 惠氏控股公司 作为egf－r和her2激酶抑制剂的3－氰基喹啉

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003296414A1 (en) * 2002-12-12 2004-07-09 Pharmacia Corporation Method of using aminocyanopyridine compounds as mitogen activated protein kinase-activated protein kinase-2 inhibitors
AU2006247520A1 (en) * 2005-05-18 2006-11-23 Wyeth 3-cyanoquinoline inhibitors of TPL2 kinase and methods of making and using the same

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1320121A (zh) * 1998-09-29 2001-10-31 美国氰胺公司 作为蛋白质酪氨酸激酶抑制剂的取代的3－氰基喹啉
CN1659145A (zh) * 2001-11-27 2005-08-24 惠氏控股公司 作为egf－r和her2激酶抑制剂的3－氰基喹啉

Also Published As

Publication number Publication date
AU2007258237A1 (en) 2007-12-21
CA2654515A1 (en) 2007-12-21
CA2654515C (en) 2014-04-01
ES2558706T3 (es) 2016-02-08
TW200815407A (en) 2008-04-01
EP2029543B1 (en) 2015-11-18
MX2008015802A (es) 2009-01-09
NO20084739L (no) 2009-01-06
EP2029543A2 (en) 2009-03-04
WO2007146376A2 (en) 2007-12-21
RU2008139079A (ru) 2010-07-20
WO2007146376A3 (en) 2008-03-13
KR20090018612A (ko) 2009-02-20
CN101466678A (zh) 2009-06-24
JP2009539998A (ja) 2009-11-19
ZA200810573B (en) 2009-09-30
AR061368A1 (es) 2008-08-20
IL194625A0 (en) 2009-08-03
PE20080336A1 (es) 2008-06-03
BRPI0712737A2 (pt) 2012-05-08
CL2007001737A1 (es) 2008-01-25

Similar Documents

Publication Publication Date Title
US7781591B2 (en) Substituted 3-cyanopyridines as protein kinase inhibitors
EP2044051B1 (en) Pyridine and pyrazine derivatives as mnk kinase inhibitors
KR102311573B1 (ko) 브로모도메인 억제제
RU2422449C2 (ru) Фармацевтические соединения
CN109310671B (zh) 布鲁顿酪氨酸激酶抑制剂
CN104725397B (zh) 噻吩并嘧啶衍生物、其制备方法以及含有它们的药用组合物
CN111989311B (zh) 抑制pge2/ep4信号传导的化合物、其制备方法及其在医药上的应用
CN105189480A (zh) 在治疗由IKKε和/或TBK-1机制介导的疾病中有用的嘧啶化合物
WO2007023768A1 (ja) 新規ピリジン誘導体およびピリミジン誘導体（３）
EP3068758B1 (en) Ebna1 inhibitors and their method of use
MX2011000738A (es) 3,4-diarilpirazoles como inhibidoers de proteina cinasa.
KR20100017362A (ko) Ｐｉｍ 조절제로서 ６­페닐피리미디논
KR20070026357A (ko) 인돌 유도체, 및 키나제 억제제, 특히 ｉｋｋ2억제제로서의 그의 용도
WO2009076602A1 (en) 5-alkyl/alkenyl-3-cyanopyridines as kinase inhibitors
EP2029543B1 (en) Substituted 3-cyanopyridines as protein kinase inhibitors
CN101454287A (zh) 作为蛋白激酶抑制剂的经取代氰基吡啶
US20070287738A1 (en) Substituted Cyanopyridines as protein kinase inhibitors
WO2009076571A1 (en) Indole-substituted 3-cyanopyridines as kinase inhibitors
CN121263410A (zh) 作为sik抑制剂的苯并呋喃衍生物以及其用途
HK40051501B (en) Compound for inhibiting pge2/ep4 signaling transduction inhibiting, preparation method therefor, and medical uses thereof
HK1129043A (en) Pyridine and pyrazine derivatives as mnk kinase inhibitors
MXPA06008080A (en) Indole derivatives and use thereof as kinase inhibitors in particular ikk2 inhibitors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20121226

Termination date: 20160613

CF01 Termination of patent right due to non-payment of annual fee